原发性肿瘤位置作为转移性结直肠癌（mCRC）的预后和预测标志物
Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC).
作者信息
Bahl Ankur, Talwar Vineet, Sirohi Bhawna, Mehta Prashant, Arya Devavrat, Shrivastava Gunjan, Dahiya Akhil, Pavithran K
机构信息
Department of Medical Oncology, Max Super Speciality Hospital, New Delhi, India.
Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India.
出版信息
Front Oncol. 2020 Jun 16;10:964. doi: 10.3389/fonc.2020.00964. eCollection 2020.
Abstract
Clinico-pathological differences between adenocarcinoma in the right and left colo-rectum play a role in determining the prognosis and response to treatment. Studies suggest that primary tumor location is more relevant as the disease progresses and reflects a possible difference in biology and response to therapy. This review aims to explore the clinico-pathological features of right and left colo-rectum and the impact of primary tumor location on prognosis of CRC as well as discuss the available clinical data on tumor sidedness in metastatic colorectal cancer. In so far as the clinical data of tumor sidedness is concerned, very few reviews have discussed the clinical implications of sidedness in heavily pre-treated metastatic colorectal cancer (second and subsequent lines of therapy in metastatic disease). This review aims to fill the current gap in this setting.
摘要
左右侧结直肠癌的临床病理差异在决定预后和治疗反应方面发挥着作用。研究表明，随着疾病进展，原发肿瘤位置更为重要，且反映出生物学特性及对治疗反应方面可能存在的差异。本综述旨在探讨左右侧结直肠癌的临床病理特征、原发肿瘤位置对结直肠癌预后的影响，并讨论转移性结直肠癌中肿瘤部位的现有临床数据。就肿瘤部位的临床数据而言，很少有综述讨论过在接受过大量预处理的转移性结直肠癌（转移性疾病的二线及后续治疗）中部位的临床意义。本综述旨在填补这一领域目前的空白。
相似文献
1
Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC).原发性肿瘤位置作为转移性结直肠癌（mCRC）的预后和预测标志物
Front Oncol. 2020 Jun 16;10:964. doi: 10.3389/fonc.2020.00964. eCollection 2020.
2
Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie).抗 EGFR 而非抗 VEGF 治疗的 mCRC 中，侧别和 TP53 突变影响 OS - KRAS 登记处的 AGMT（药物治疗肿瘤学工作组）分析。
BMC Cancer. 2018 Jan 3;18(1):11. doi: 10.1186/s12885-017-3955-4.
3
Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.基于西妥昔单抗联合奥沙利铂化疗治疗转移性结直肠癌的原发肿瘤部位对临床结局的预后影响：JACCRO CC-05/06 试验的亚组分析。
Clin Colorectal Cancer. 2017 Sep;16(3):e171-e180. doi: 10.1016/j.clcc.2016.09.010. Epub 2016 Oct 6.
4
The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents.原发性肿瘤部位在接受靶向药物治疗的转移性结直肠癌中的预测作用。
Anticancer Res. 2019 Oct;39(10):5645-5652. doi: 10.21873/anticanres.13761.
5
Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer.转移性结直肠癌患者肿瘤负荷独立预测 EGFR 精准靶向治疗的预后。
J Natl Compr Canc Netw. 2018 Dec;16(12):1442-1450. doi: 10.6004/jnccn.2018.7074.
6
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study.一线化疗联合抗表皮生长因子受体（EGFR）或抗血管内皮生长因子（VEGF）单克隆抗体治疗RAS野生型转移性结肠癌患者时原发肿瘤部位的影响：一项回顾性多中心研究
J Cancer. 2019 Oct 15;10(24):5926-5934. doi: 10.7150/jca.34550. eCollection 2019.
7
Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy.皮肤疾病和原发肿瘤位置作为接受西妥昔单抗和化疗的转移性结直肠癌患者的预后因素
Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2325-2330. doi: 10.22034/APJCP.2018.19.8.2325.
8
The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients with Metastatic Colorectal Cancer.微卫星不稳定性状态及原发肿瘤部位对转移性结直肠癌患者含西妥昔单抗化疗疗效的影响
J Cancer. 2017 Aug 23;8(14):2809-2815. doi: 10.7150/jca.18286. eCollection 2017.
9
Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies.优化抗表皮生长因子受体（EGFR）和血管内皮生长因子（VEGF）单克隆抗体序贯治疗转移性结直肠癌：当前结果与争议
Cancer Manag Res. 2019 Feb 19;11:1705-1716. doi: 10.2147/CMAR.S196170. eCollection 2019.
10
Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.四项随机帕尼单抗研究中 RAS 野生型转移性结直肠癌患者二线或以上治疗结局与所有治疗线中 RAS 突变患者的原发肿瘤位置的影响。
Clin Colorectal Cancer. 2018 Sep;17(3):170-178.e3. doi: 10.1016/j.clcc.2018.03.005. Epub 2018 Mar 8.
引用本文的文献
1
Survival Predictors in Obstructive Colorectal Cancer: A Combined Clinical, Inflammatory, and Histopathological Approach.梗阻性结直肠癌的生存预测因素：临床、炎症和组织病理学联合研究方法
In Vivo. 2025 Jul-Aug;39(4):2419-2428. doi: 10.21873/invivo.14041.
2
Efficacy and safety of trifluridine/tipiracil plus bevacizumab across different subgroups of patients with refractory colorectal cancer: a meta-analysis.曲氟尿苷/替匹嘧啶联合贝伐单抗治疗难治性结直肠癌不同亚组患者的疗效与安全性：一项荟萃分析
Ecancermedicalscience. 2024 Jul 10;18:1728. doi: 10.3332/ecancer.2024.1728. eCollection 2024.
3
Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.转移性结直肠癌的共识分子亚型可扩大 CMS1 和 CMS2 肿瘤患者基于生物标志物的治疗获益。
Br J Cancer. 2024 Nov;131(8):1328-1339. doi: 10.1038/s41416-024-02826-0. Epub 2024 Sep 4.
4
Label-free quantification of imaging features in the extracellular matrix of left and right-sided colon cancer tissues.无标记定量分析左、右侧结肠癌组织细胞外基质的影像学特征。
Sci Rep. 2024 Mar 29;14(1):7510. doi: 10.1038/s41598-024-58231-3.
5
Primary Tumor Resection Plus Chemotherapy versus Chemotherapy Alone for Colorectal Cancer Patients with Synchronous Bone Metastasis.原发肿瘤切除联合化疗与单纯化疗治疗结直肠癌合并骨转移患者的比较。
Medicina (Kaunas). 2023 Jul 28;59(8):1384. doi: 10.3390/medicina59081384.
6
Clinicopathological Profiles Associated with Discordant Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer.在转移性结直肠癌真实世界队列中，液体活检与组织活检之间突变状态不一致的临床病理特征
Cancers (Basel). 2023 Jul 12;15(14):3578. doi: 10.3390/cancers15143578.
7
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis.转移性结直肠癌患者单纯细胞毒性化疗或联合靶向治疗反应的人工智能预测模型：系统评价与荟萃分析
Cancers (Basel). 2022 Aug 19;14(16):4012. doi: 10.3390/cancers14164012.
8
Bevacizumab in metastatic colorectal cancer in a real-life setting - toxicity profile, survival outcomes, and impact of tumor sidedness.现实环境中贝伐单抗治疗转移性结直肠癌——毒性特征、生存结果及肿瘤部位的影响
Contemp Oncol (Pozn). 2022;26(1):32-39. doi: 10.5114/wo.2022.114678. Epub 2022 Mar 18.
9
Advances in CpG Island Methylator Phenotype Colorectal Cancer Therapies.CpG岛甲基化表型结直肠癌治疗的进展
Front Oncol. 2021 Feb 26;11:629390. doi: 10.3389/fonc.2021.629390. eCollection 2021.
本文引用的文献
1
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.结直肠癌的共识分子亚群（CMS）和 FOLFIRI 联合西妥昔单抗或贝伐珠单抗一线治疗在 FIRE3（AIO KRK-0306）试验中的疗效。
Ann Oncol. 2019 Nov 1;30(11):1796-1803. doi: 10.1093/annonc/mdz387.
2
Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.伴有 和 野生型转移性结直肠癌患者接受帕尼单抗维持治疗的负性选择。
J Clin Oncol. 2019 Nov 20;37(33):3099-3110. doi: 10.1200/JCO.19.01254. Epub 2019 Sep 20.
3
Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients.原发性肿瘤部位可预测贝伐单抗对转移性结直肠癌患者的疗效。
Front Oncol. 2019 Aug 14;9:723. doi: 10.3389/fonc.2019.00723. eCollection 2019.
4
The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer.原发性肿瘤部位对瑞戈非尼治疗难治性转移性结直肠癌疗效的影响
J Cancer. 2019 Mar 3;10(7):1611-1615. doi: 10.7150/jca.29106. eCollection 2019.
5
Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma.右半结肠癌和左半结肠癌在总生存率和突变发生率上的差异。
J Gastrointest Oncol. 2018 Oct;9(5):778-784. doi: 10.21037/jgo.2018.06.10.
6
Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER-Based Analysis.结直肠癌中肿瘤侧别的预后影响：基于 SEER 的分析。
Clin Colorectal Cancer. 2019 Mar;18(1):e104-e116. doi: 10.1016/j.clcc.2018.10.005. Epub 2018 Oct 27.
7
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
8
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO.原发性肿瘤部位与FOLFOXIRI联合贝伐单抗作为转移性结直肠癌初始治疗的获益。GONO对TRIBE试验的回顾性分析。
Ann Oncol. 2018 Jul;29(7):1528-1534. doi: 10.1093/annonc/mdy140. Epub 2018 Apr 20.
9
Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies.四项随机帕尼单抗研究中 RAS 野生型转移性结直肠癌患者二线或以上治疗结局与所有治疗线中 RAS 突变患者的原发肿瘤位置的影响。
Clin Colorectal Cancer. 2018 Sep;17(3):170-178.e3. doi: 10.1016/j.clcc.2018.03.005. Epub 2018 Mar 8.
10
Comparison of survival between right-sided and left-sided colon cancer in different situations.不同情况下右侧结肠癌与左侧结肠癌的生存比较。
Cancer Med. 2018 Apr;7(4):1141-1150. doi: 10.1002/cam4.1401. Epub 2018 Mar 13.
Zotero 插件